Loading stock…

Regeneron Pharmaceuticals, Inc. (REGN) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Regeneron Pharmaceuticals, Inc.

REGNMarket cap $74BPrice $742.1

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops breakthrough drugs for cancer, eye diseases, and rare conditions using proprietary mouse technology that produces human antibodies. Their COVID treatments and eye drugs generate billions while serving millions of patients worldwide.

In Bastion Portfolios?

52W Return+29%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+6%5

Revenue Forecast

Rev CAGR (1y)+19%8

Rev CAGR (3y)+12%7

Rev CAGR (5y)+10%7

Earnings Forecast

EPS Growth Y+1+43%9

EPS Growth Y+2+11%7

EPS Growth Y+3+12%7

Quality

Margins

EBIT Margin27%8

Net Income Margin28%9

Free Cash Flow Margin24%9

Debt

Net Debt/EBITDA-3.210

Efficiency

ROE14%6

ROA11%9

Earnings Stability55

GEAR+VERY STRONG98

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)118

P/E Ratio (Forward 3y)108

P/BV2.36

EV Multiples

EV/EBITDA Fwd78

EV/EBIT Fwd89

Yield

Free Cash Flow Yield5.1%6

Dividend Yield0.5%2

Momentum

Short term

1 month return-8%3

3 month return+12%9

YTD return-3%4

Mid term

Price vs 52wHigh86%7

1 year return+32%8

Long term

3 year return-10%2

5 year return+36%5

Risk Shield

Price Risk

Beta0.67

Volatility33%6

Free Cash Flow

Free Cash Flow Margin24%9

Free Cash Flow Yield5.1%6

Quality

ROCE12%6

Earnings Stability55

Net Debt/EBITDA-3.210

02Growth

Is it actually growing, and how fast?

REGNRegeneron Pharmaceuticals

Revenue FY25$14.3B

GROWTH RATING↗

STRONG69 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+19%8

Revenue, next 3Y, CAGR+12%7

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+43%9

EPS growth, FY27E+11%7

EPS growth, FY28E+12%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 69% of companies worldwide.

Revenue is set to grow 12%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 6%/yr over the last 3 years and is set to grow 12%/yr from here.

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 12%/yr vs revenue 12%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Reaccelerating Grower

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE55 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return+12%9

YTD return-3%4

MID & LONG-TERM▾SCORE

% of 52-week high86%7

1-year return+32%8

3-year return-10%2

5-year return+36%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 32% over the past year, but 14% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+12%).

WATCH

Returns sit at the market level so far this year (-3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-10% over three years and +36% over five), behind 60% of the market.

The stock is underperforming over the past month (-8%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Regeneron Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

REGNRegeneron Pharmaceuticals

Revenue FY25$14.3B

GROWTH RATING↗

STRONG69 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+19%8

Revenue, next 3Y, CAGR+12%7

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+43%9

EPS growth, FY27E+11%7

EPS growth, FY28E+12%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 69% of companies worldwide.

Revenue is set to grow 12%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 6%/yr over the last 3 years and is set to grow 12%/yr from here.

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 12%/yr vs revenue 12%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Reaccelerating Grower

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE55 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return+12%9

YTD return-3%4

MID & LONG-TERM▾SCORE

% of 52-week high86%7

1-year return+32%8

3-year return-10%2

5-year return+36%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 32% over the past year, but 14% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+12%).

WATCH

Returns sit at the market level so far this year (-3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-10% over three years and +36% over five), behind 60% of the market.

The stock is underperforming over the past month (-8%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Regeneron Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community